Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2022-09-29 Regulatory Filings
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT-EXCLUSIVE LICENSING AGREEMENT OF SIM0278 WITH ALMIRALL S.A. FOR RIGHTS OUTSIDE GREATER CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited about entering into an exclusive licensing agreement with Almirall S.A. It details the terms of the agreement, the product involved, and background information about both companies. There is no financial data, no regulatory certification, no voting results, no management changes, no earnings or interim report data, and no mention of a report being attached or published. The content is clearly an announcement of a business development related to licensing and collaboration, which fits best under a general regulatory announcement category. It does not fit into any specific financial report or meeting-related category. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 5294 characters, which is sufficient for a substantive announcement rather than a brief notice or report publication announcement.
2022-09-29 English
GRANT OF AWARDS AND ISSUE OF NEW SHARES UNDER THE 2021 RSU SCHEME
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding the grant of awards and the issue of new shares under the 2021 RSU Scheme. It details the number of restricted share units (RSUs) granted, the vesting schedule, trustees involved, and the application for listing of new shares. The content focuses on share issuance related to employee incentive schemes and does not contain financial statements or detailed financial performance data. It is not a full financial report, earnings release, or management discussion. The document is a formal announcement about share issuance and awards under a share scheme, which fits the category of Share Issue/Capital Change (SHA). The document length is 9590 characters, which is substantial and contains detailed information about the share issuance event itself, not just a brief notice or a report publication announcement. Therefore, the appropriate classification is SHA with high confidence.
2022-09-28 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return filing related to movements in securities for Simcere Pharmaceutical Group Limited, specifically detailing movements in issued shares, share options, and other share-related information for the month ended 31 August 2022. It is addressed to the Hong Kong Exchanges and Clearing Limited and follows the format of a regulatory return under the Exchange Listing Rules. The content focuses on share capital movements and confirmations, with no financial statements, earnings data, or management discussion. It is not an annual or interim report, earnings release, or investor presentation. It is also not a proxy, voting result, or remuneration report. The document is a regulatory filing reporting share capital movements and related confirmations, fitting the category of Regulatory Filings (RNS). The document length is about 5,000 characters, and it contains substantive data on share movements, not just an announcement of a report publication.
2022-09-05 English
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2022
Interim / Quarterly Report Classification · 95% confidence The document is titled 'ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2022' and contains detailed financial highlights, business highlights, management discussion and analysis, and operational milestones for the six-month period ending June 30, 2022. It includes unaudited condensed consolidated financial results, revenue breakdowns, product information, and clinical trial updates. The length is substantial (15,000 characters), and the content includes substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). It is not a brief announcement or a certification, nor is it a full annual report or earnings release. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-31 English
FURTHER CHANGE IN USE OF PROCEEDS
Capital/Financing Update Classification · 95% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding a further change in the use of proceeds from their Global Offering and over-allotment option. It references previous announcements and the prospectus related to the company's IPO and fundraising activities. The content focuses on reallocating unutilized net proceeds among different R&D projects and provides detailed financial figures on the use of proceeds. There is no presentation of full financial statements or comprehensive financial performance data typical of an annual or interim report. Instead, it is an update on capital usage and fundraising proceeds allocation. The document is about changes in the use of capital raised, which fits the category of Capital/Financing Update (CAP). The document length is substantial (over 11,000 characters), and it contains detailed financial data related to capital use, not just a brief announcement or a certification. Therefore, the best classification is CAP with high confidence.
2022-08-31 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles and functions, including committee memberships. It is a formal announcement of the board composition and committee structure. There is no financial data, no report content, no voting results, no legal proceedings, or other types of filings. This fits the definition of Board/Management Information (MANG), which covers announcements of changes or details about the company's board of directors or senior management. The document is short (1209 characters) and purely informational about the board structure, not a report or presentation. Therefore, the correct classification is MANG with high confidence.
2022-08-31 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.